Patient voice on management of facial dermatological adverse events with targeted therapies: a qualitative study

Research output: Contribution to journalArticle

Abstract

Background: With the increased use of targeted therapies in oncology, dermatological adverse events (dAEs) have drawn attention. Because the face is crucial for human identity and social interactions, facial dAEs have significant impact on a patient’s quality of life. This study aimed to explore patients’ experience with regard to the management of targeted oncological therapy-induced facial dAEs. Methods: In this qualitative study, 20 patients at a university hospital in Japan with advanced/metastatic cancer and targeted therapy-induced facial dAEs were individually interviewed to collect data. Thematic analysis was used to analyze the data. Results: Patients with cancer and targeted oncological therapy-induced facial dAEs who were referred to the Department of Dermatology had certain expectations from specialist services. Three key themes were identified: professional input and advice, empathetic commitment to individual management, and integrated care across specialties. Conclusions: The referred patients with cancer and facial dAEs needed more in-depth information and advice from dermatological services and were reassured by the empathetic commitment to individual management in integrated care across specialties. These findings suggest that attention to the patient’s perspective with a “sick person first” attitude and a collaborative effort across different specialties is important to minimize the effects of facial dAEs on the quality of life of patients with cancer.

Original languageEnglish
Article number27
JournalJournal of Patient-Reported Outcomes
Volume3
Issue number1
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

Therapeutics
Neoplasms
Quality of Life
Interpersonal Relations
Dermatology
Japan

Keywords

  • Dermatological adverse events
  • Integrated care
  • Patient-centered care
  • Qualitative study
  • Quality of life
  • Targeted therapies

ASJC Scopus subject areas

  • Health Informatics
  • Health Information Management

Cite this

@article{04228f67ed8b4a74818cc601751b17b9,
title = "Patient voice on management of facial dermatological adverse events with targeted therapies: a qualitative study",
abstract = "Background: With the increased use of targeted therapies in oncology, dermatological adverse events (dAEs) have drawn attention. Because the face is crucial for human identity and social interactions, facial dAEs have significant impact on a patient’s quality of life. This study aimed to explore patients’ experience with regard to the management of targeted oncological therapy-induced facial dAEs. Methods: In this qualitative study, 20 patients at a university hospital in Japan with advanced/metastatic cancer and targeted therapy-induced facial dAEs were individually interviewed to collect data. Thematic analysis was used to analyze the data. Results: Patients with cancer and targeted oncological therapy-induced facial dAEs who were referred to the Department of Dermatology had certain expectations from specialist services. Three key themes were identified: professional input and advice, empathetic commitment to individual management, and integrated care across specialties. Conclusions: The referred patients with cancer and facial dAEs needed more in-depth information and advice from dermatological services and were reassured by the empathetic commitment to individual management in integrated care across specialties. These findings suggest that attention to the patient’s perspective with a “sick person first” attitude and a collaborative effort across different specialties is important to minimize the effects of facial dAEs on the quality of life of patients with cancer.",
keywords = "Dermatological adverse events, Integrated care, Patient-centered care, Qualitative study, Quality of life, Targeted therapies",
author = "Kaori Yagasaki and Hayato Takahashi and Takeshi Ouchi and Jun Yamagami and Yasuo Hamamoto and Masayuki Amagai and Hiroko Komatsu",
year = "2019",
month = "12",
day = "1",
doi = "10.1186/s41687-019-0116-3",
language = "English",
volume = "3",
journal = "Journal of Patient-Reported Outcomes",
issn = "2509-8020",
number = "1",

}

TY - JOUR

T1 - Patient voice on management of facial dermatological adverse events with targeted therapies

T2 - a qualitative study

AU - Yagasaki, Kaori

AU - Takahashi, Hayato

AU - Ouchi, Takeshi

AU - Yamagami, Jun

AU - Hamamoto, Yasuo

AU - Amagai, Masayuki

AU - Komatsu, Hiroko

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Background: With the increased use of targeted therapies in oncology, dermatological adverse events (dAEs) have drawn attention. Because the face is crucial for human identity and social interactions, facial dAEs have significant impact on a patient’s quality of life. This study aimed to explore patients’ experience with regard to the management of targeted oncological therapy-induced facial dAEs. Methods: In this qualitative study, 20 patients at a university hospital in Japan with advanced/metastatic cancer and targeted therapy-induced facial dAEs were individually interviewed to collect data. Thematic analysis was used to analyze the data. Results: Patients with cancer and targeted oncological therapy-induced facial dAEs who were referred to the Department of Dermatology had certain expectations from specialist services. Three key themes were identified: professional input and advice, empathetic commitment to individual management, and integrated care across specialties. Conclusions: The referred patients with cancer and facial dAEs needed more in-depth information and advice from dermatological services and were reassured by the empathetic commitment to individual management in integrated care across specialties. These findings suggest that attention to the patient’s perspective with a “sick person first” attitude and a collaborative effort across different specialties is important to minimize the effects of facial dAEs on the quality of life of patients with cancer.

AB - Background: With the increased use of targeted therapies in oncology, dermatological adverse events (dAEs) have drawn attention. Because the face is crucial for human identity and social interactions, facial dAEs have significant impact on a patient’s quality of life. This study aimed to explore patients’ experience with regard to the management of targeted oncological therapy-induced facial dAEs. Methods: In this qualitative study, 20 patients at a university hospital in Japan with advanced/metastatic cancer and targeted therapy-induced facial dAEs were individually interviewed to collect data. Thematic analysis was used to analyze the data. Results: Patients with cancer and targeted oncological therapy-induced facial dAEs who were referred to the Department of Dermatology had certain expectations from specialist services. Three key themes were identified: professional input and advice, empathetic commitment to individual management, and integrated care across specialties. Conclusions: The referred patients with cancer and facial dAEs needed more in-depth information and advice from dermatological services and were reassured by the empathetic commitment to individual management in integrated care across specialties. These findings suggest that attention to the patient’s perspective with a “sick person first” attitude and a collaborative effort across different specialties is important to minimize the effects of facial dAEs on the quality of life of patients with cancer.

KW - Dermatological adverse events

KW - Integrated care

KW - Patient-centered care

KW - Qualitative study

KW - Quality of life

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=85077536496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077536496&partnerID=8YFLogxK

U2 - 10.1186/s41687-019-0116-3

DO - 10.1186/s41687-019-0116-3

M3 - Article

AN - SCOPUS:85077536496

VL - 3

JO - Journal of Patient-Reported Outcomes

JF - Journal of Patient-Reported Outcomes

SN - 2509-8020

IS - 1

M1 - 27

ER -